ArticleThe Journal of antimicrobial chemotherapy2026
Quinolones and risk of haemolysis in patients with glucose-6-phosphate dehydrogenase deficiency: a nationwide retrospective active-comparator cohort study.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundQuinolone product information and avoidance lists continue to caution against use in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency despite limited comparative epidemiologic evidence. We evaluated whether oral quinolone dispensations were associated with haemolysis-related outcomes compared with an active antibiotic comparator.
methodsWe conducted a nationwide retrospective active-comparator cohort study using Clalit Health Services data from 2010 to 2023. Patients with at least one ICD-coded diagnosis of G6PD deficiency who received an outpatient oral quinolone or penicillin dispensation were included. The primary outcome was a haemolysis-related diagnosis code recorded within 30 days. Jaundice and laboratory markers were secondary outcomes. Models were adjusted for age, sex and Charlson comorbidity index. Additional analyses evaluated patients aged 18 years or younger, patients exposed to both antibiotic classes and individual quinolone agents.
resultsThe cohort included 465 083 dispensations among 64 861 patients (65 906 quinolone and 399 177 penicillin episodes). Haemolysis-related codes were recorded after 52 quinolone episodes (0.079%) and 198 penicillin episodes (0.050%); the adjusted odds ratio (aOR) was 1.29 [95% confidence interval (CI) 0.92-1.77; P = 0.12]. Among patients aged 18 years or younger, events occurred after 5/8865 quinolone and 91/160 423 penicillin episodes (aOR 1.02, 95% CI 0.36-2.26, P = 0.970). In the within-patient subcohort, episode-level event rates were 0.065% after quinolones and 0.061% after penicillins (aOR 0.95, 95% CI 0.65-1.37, P = 0.785). Laboratory outcomes did not show a coherent pattern of increased haemolysis after quinolones.
conclusionsIn this large outpatient cohort, oral quinolone dispensations were not associated with a detectable major increase in coded haemolysis compared with penicillins. The findings do not exclude small risks or increased susceptibility in patients with severe G6PD deficiency, very young children, active infection-related oxidative stress or concurrent oxidant exposures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.